NuPotential has generated a broad-scoped and leading patent family around small molecule inhibition of epigenetic factors related to single carbon metabolism (methionine cycle) and other epigenomic modifying targets affecting cellular reprogramming potential. Some of the same epigenetic enzymes targeted by NuPotential's novel and proprietary NP-Epidrug libraries, including histone deactylases (HDAC), sirtuins (SIRT), and histone methyltransferases (HMT) are strongly associated with the underlying causes of multiple human chronic diseases such as type 2 diabetes, obesity, cancer, Alzheimer's and Parkinson's.  As such, NuPotential is leveraging its PIER and NP-Reprog platforms to broaden the current epidrug market with NP-Epidrugs, a highly selective, novel and proprietary class of pharmaceuticals that target epigenetic factors of chronic disease. 

NP-Epidrugs are drug-like, lead small molecule compounds developed to be first in class, and best in class therapies of chronic diseases including type 2 diabetes, obesity and cancer.  NuPotential's "unique and unprecedented" PIER epidrug discovery and NP-Reprog cell reprogramming platforms provide the company a clear advantage in uncovering NP-Epidrug targets involved in epigenomic maintenance ("Persistent Epigenetic Memory").  As a result, NP-Epidrugs can be designed to selectively target disease pathways at their epigenetic core to decouple aberrant epigenomic modifications that cause abnormal physiologies associated with disease onset and progression.   Strong working relationships with reputable medicinal chemistry CRO's ensures that all lead NP-Epidrugs are synthesized and optimized for; 1) high target selectivity; 2) novelty (freedom to operate); and 3) applicability, efficacy (clinical readiness).  

Additional NP-Epidrug highlights include:

• Improved target selectivity and thus  enhanced therapeutic efficacy/safety profiles.
• High potential for improving current cancer therapies as well as advancing cancer-related differentiation therapies into new markets.
• Potential as first in class/best in class therapies for type 2 diabetes and obesity.
• Design/Synthesis/Characterization by world renowned medicinal chemistry CRO's. 
• PIER and NP-Reprog driven technology.
• Strong IP support.

NuPotential has identified several selective NP-Epidrugs within its current libraries as therapeutic candidates for type 2 diabetes, obesity and cancer.  Following successful preclinical evaluation, lead compounds will be navigated into clinical trials.   NuPotential welcomes the opportunity to discuss potential collaborative and/or strategic partnerships to advance lead NP-Epidrugs into clinical studies and beyond.